-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DY1o1GjT4tZ52N5b/f6B1yfu1vOzd8PzK4qHasY2Ygj5epEuVdJRcpE4/T5jaARs l7YxzF8rl6GuZZ8hSFUj/Q== 0000950133-04-002541.txt : 20040628 0000950133-04-002541.hdr.sgml : 20040628 20040628172818 ACCESSION NUMBER: 0000950133-04-002541 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040628 ITEM INFORMATION: Other events FILED AS OF DATE: 20040628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GUILFORD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000918066 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521841960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23736 FILM NUMBER: 04886306 BUSINESS ADDRESS: STREET 1: 6611 TRIBUTARY ST CITY: BALTIMORE STATE: MD ZIP: 21224 BUSINESS PHONE: 4106316300 8-K 1 w98672e8vk.htm FORM 8-K e8vk
 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

                                                             Date of Report (Date of earliest event reported): June 28, 2004

GUILFORD PHARMACEUTICALS INC.
(Exact name of registrant as specified in its
charter)

         
Delaware   0-23736   52-1841960
(State or other jurisdiction of   (Commission File   I.R.S. Employer
incorporation or organization)  
               Number)
       Identification No.)
     
6611 Tributary Street
    
Baltimore, Maryland
 
21224
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (410) 631-6300

(Former name or former address, if changed since last report)

-1-

 

INFORMATION TO BE INCLUDED IN THE REPORT

Item 5. Other Events.

On June 28, 2004, the Company announced the appointment of William F. Spengler as Executive Vice President and Chief Financial Officer. Mr. Spengler will report to Craig R. Smith, M.D., Chairman, President and Chief Executive Officer of Guilford; his appointment is effective July 15.

Mr. Spengler, age 49 served fourteen years at Bristol-Myers Squibb (BMS) Corporation, where he was responsible for overseeing mergers and acquisitions and the development of joint venture relationships. Subsequently, Mr. Spengler served as Vice President of Finance at The Black & Decker Corporation and was responsible for the financial management of its largest product group with $1.4 billion in annual sales. He served as Chief Financial Officer of Sweetheart Cup Company from April 1997 to April 1998; Chief Financial Officer of Earthshell Corporation from April 1998 to November 1999; and a Principal of North Charles Investment Company from January 2000 to June 2002. Most recently, Mr. Spengler has served as President, COO and Director of Osteoimplant Technology, Inc., a private company, since July 2002.

Mr. Spengler received his MBA in accounting from New York University and a Bachelor of Arts in economics from Yale University.

-2-

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
 
Guilford Pharmaceuticals Inc.
 
    
Date: June 28, 2004
 
By: /s/ Asher M. Rubin
 
Asher M. Rubin
 
Vice President, General Counsel
 
and Secretary

-3-

-----END PRIVACY-ENHANCED MESSAGE-----